EQRX - EQRx, Inc. Stock Price, Fair Value and News

$2.34

Market Closed

EQRX Stock Valuation Analysis

Valuation

Max Portfolio %

EQRX Price Action

EQRX RSI Chart

EQRX Stock Valuation Analysis

Valuation

Max Portfolio %

EQRX Valuation

EQRX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

EQRX Fundamentals

EQRX Revenue

EQRX Earnings

EQRX Profitability

EQRX Investor Care

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	40.4M	52.4M	60.7M	0
2022	6.6M	12.8M	19.0M	25.1M
2021	181.8K	266.5K	351.3K	436.0K
2020	0	0	0	97.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About EQRx, Inc.

EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's clinical programs in pipeline includes Aumolertinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); Sugemalimab, is an anti-programmed cell death-ligand 1 (PD-L1) monoclonal antibody that treats stage III and stage IV NSCLC; and Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which has completed Phase 1 clinical trial in patients with metastatic breast cancer, as well as in combination with other targeted therapies for the treatment of patients with hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer. Its other programs in pipeline comprises clinical and pre-clinical, and discovery stage assets, such as Nofazinlimab, an anti-programmed death-1 (PD-1) antibody that is in Phase 3 trial for the treatment of patients with primary liver cancer, and for the treatment of patients with hepatocellular carcinoma; and EQ121, a selective Janus kinase-1 (JAK-1) inhibitor that has completed Phase 1 and in various Phase 1b and 2 trials in for the treatment of ankylosing spondylitis, atopic dermatitis, and rheumatoid arthritis. EQRx, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

CEO	Ms. Melanie I. Nallicheri
WEBSITE	eqrx.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	362